
Contraceptives Market Share, Size, Industry Trends, Growth, Forecast To 2030
Global Contraceptives Market – By Age group, By Product, By Distribution-Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
Published: Sep-2022 | Report ID: HLCA2208 | Pages: 1 - 295 | Formats*: |
Category : Healthcare |
Report Metric | Details |
Market size available for years | 2019-2030 |
Base year considered | 2021 |
Forecast period | 2022-2030 |
Segments covered | By Age group, By Product, By Distribution |
Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Companies Covered | Agile Therapeutics, Allergan PLC., Bayer AG, GalaxoSmithKline PLC., Johnson & Johnson, Mylan N.V., Mankind Pharma, Novartis AG, Piramal Healthcare, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd. |
1.1. Scope of the report1.2. Market segment analysis
2.1 Research data source
2.1.1 Secondary data2.1.2 Primary data2.1.3 SPER’s internal database2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers4.1.2 Restraints4.1.3 Opportunities4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Contraceptives market
5.1. SWOT analysis
5.1.1 Strengths5.1.2 Weaknesses5.1.3 Opportunities5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape5.2.2 Economic landscape5.2.3 Social landscape5.2.4 Technological landscape5.2.5 Environmental landscape5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers5.3.2 Bargaining power of Buyers5.3.3 Threat of Substitute5.3.4 Threat of new entrant5.3.5 Competitive rivalry
5.4. Heat map analysis
6.1. 15-24 Years6.2. 25-34 Years6.3. 35-44 Years6.4. 44 Years
7.1. Oral Contraceptive Pills7.2. Intra-Uterine Devices7.3. Contraceptive Sponges7.4. Subdermal Implants7.5. Vaginal Rings7.6. Condoms7.7. Topical Contraceptives7.8. Injectables7.9. Diaphragms
8.1. Hospital Pharmacies8.2. Online Pharmacies8.3. Independent Pharmacies8.4. Clinics8.5. Others
9.1. North America
9.1.1. United States9.1.2. Canada9.1.3. Mexico
9.2. Europe9.2.1. Germany
9.2.2. United Kingdom9.2.3. France9.2.4. Italy9.2.5. Spain9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China9.3.2. Japan9.3.3. India9.3.4. Australia9.3.5. South Korea9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil9.4.2. Argentina9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia9.5.2. United Arab Emirates9.5.3. Rest of Middle East & Africa
10.1. Agile Therapeutics
10.1.1. Company details10.1.2. Financial outlook10.1.3. Product summary10.1.4. Recent developments
10.2. Allergan PLC.
10.2.1. Company details10.2.2. Financial outlook10.2.3. Product summary10.2.4. Recent developments
10.3. Bayer AG
10.3.1. Company details10.3.2. Financial outlook10.3.3. Product summary10.3.4. Recent developments
10.4. GalaxoSmithKline PLC
10.4.1. Company details10.4.2. Financial outlook10.4.3. Product summary10.4.4. Recent developments
10.5. Johnson & Johnson
10.5.1. Company details10.5.2. Financial outlook10.5.3. Product summary10.5.4. Recent developments
10.6. Mylan N.V.
10.6.1. Company details10.6.2. Financial outlook10.6.3. Product summary10.6.4. Recent developments
10.7. Mankind Pharma
10.7.1. Company details10.7.2. Financial outlook10.7.3. Product summary10.7.4. Recent developments
10.8. Novartis AG
10.8.1. Company details10.8.2. Financial outlook10.8.3. Product summary10.8.4. Recent developments
10.9. Piramal Healthcare
10.9.1. Company details10.9.2. Financial outlook10.9.3. Product summary10.9.4. Recent developments
10.10. Pfizer Inc.
10.10.1. Company details10.10.2. Financial outlook10.10.3. Product summary10.10.4. Recent developments
10.11. Sun Pharmaceutical Industries Ltd.
10.11.1. Company details10.11.2. Financial outlook10.11.3. Product summary10.11.4. Recent developments
10.12. Teva Pharmaceutical Industries Ltd.
10.12.1. Company details10.12.2. Financial outlook10.12.3. Product summary10.12.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment






Related Reports
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.